『Daily, Tue 10 Nov: A Chinese firm comes off a Pentagon list. Is the risk gone?』のカバーアート

Daily, Tue 10 Nov: A Chinese firm comes off a Pentagon list. Is the risk gone?

Daily, Tue 10 Nov: A Chinese firm comes off a Pentagon list. Is the risk gone?

無料で聴く

ポッドキャストの詳細を見る
概要

This episode covers the US Defense Department's removal of WuXi AppTec from its 1260H list and what it does not settle, two Chinese antibody–drug conjugates in EGFR-mutated lung cancer from Biokin and Hengrui, and Vir's hepatitis delta result with the China angle through Brii Biosciences. Beyond biotech: Singapore's SG-INSIGHT genome sequencing, a two-step chemogenetic approach to drug-resistant epilepsy from Beijing, and a new FDA eye-risk warning for GLP-1 drugs.

Full transcript and all sources for this episode

Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Neither Basil nor Ning holds investments in any company mentioned.

Chapters
0:00 Intro and AI-voice disclosure
0:54 WuXi AppTec and the Pentagon list
2:33 Two Chinese ADCs in EGFR lung cancer
5:33 Hepatitis: Vir and Brii's shared drug
7:16 Beyond: Singapore's SG-INSIGHT genomes
8:19 Beyond: a chemogenetic switch for epilepsy
9:23 Beyond: FDA GLP-1 eye warning
10:06 What to watch and sign-off

Key sources: Federal Register: WuXi AppTec 1260H removal · BMS: PANKU-Lung01 (company press release) · ASCO Post: HERON-Lung01 · Vir: ECLIPSE 1 (company press release) · FDA: GLP-1 NAION safety communication (all sources on the episode page)

Weekly LinkedIn newsletter

Also listen on: Apple Podcasts · Amazon Music · YouTube

adbl_web_anon_alc_button_suppression_t1
まだレビューはありません